The Story of GLP-1: A Historical Journey in the Treatment of Diabetes and Obesity offers a compelling narrative about the discovery and development of the hormone GLP-1, which has revolutionized modern approaches to diabetes and obesity. Award-winning scientist Professor Jens Juul Holst, alongside co-authors Professor Sten Madsbad, Professor Jens Meldgaard Bruun, and Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen, trace the scientific breakthroughs and clinical advances that have made GLP-1 therapies, such as Ozempic and Wegovy, essential tools for improving blood sugar control and promoting meaningful, lasting weight loss in patients worldwide.
The book explores the rising global prevalence of obesity and diabetes, emphasizing the urgent need for innovative solutions. It critically examines traditional treatments, noting their limitations in sustaining weight loss or reducing complications. The narrative details the paradigm shift brought by GLP-1 medications, including liraglutide and semaglutide, which offer improved cardiovascular outcomes and significant health benefits. The authors also address ongoing challenges of accessibility and affordability, prompting important societal discussions about equitable distribution and funding for these lifechanging therapies.
